FL-GEG
9.7.2021 19:10:10 CEST | Business Wire | Press release
Andreas Helgstrand, CEO of Global Equestrian Group (GEG), and Mark Bellissimo, CEO of Wellington Equestrian Partners (WEP), announced an unprecedented partnership focused on developing international equestrian sport. GEG will acquire the Wellington, Florida-based Palm Beach International Equestrian Center (PBIEC) and will invest in WEP equestrian lifestyle initiatives. WEP’s largest partners, Mark Bellissimo, Roger Smith, Lisa Lourie, and Marsha Dammerman as well as Michael Stone will co-invest in GEG. Mark Bellissimo and PBIEC have transformed Wellington into the world’s premiere destination for equestrian enthusiasts, with competitions and events across more than 40 weeks every year. PBIEC is home to the Winter Equestrian Festival, spanning 13 weeks and is the world’s largest and longest-running equestrian sports event. 4,000 families, 8,000 horses, and 250,000 spectators from 43 different countries converge on Wellington to compete for over USD 12 million in prize money. A recent independent economic study highlighted the Winter Equestrian Festival’s annual economic impact on Palm Beach County of USD 279 million of total expenditures and 150,000 bed nights. GEG is part of Waterland Private Equity, who manage a global investment portfolio in excess of USD 11 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210709005400/en/
PBIEC operates 16 competition arenas, 2,500 stalls, and provides participants and spectators with a variety of exclusive restaurants, shopping, hospitality areas, and other first-class facilities. PBIEC management will remain intact with Mark Bellissimo continuing as CEO, Michael Stone as President, and David Burton as Chief Operating officer. The GEG initiative will launch major investments in all areas of the facility ensuring that PBIEC will continue to be the pre-eminent sport horse venue in the world with increased exposure in Europe, Asia, and South America. The purchase includes an 11-acre expansion of the Showgrounds. To ensure continuity, the WEP partners required a 50-year deed restriction on the venue that guarantees USEF and FEI sanctioned shows on the property. USEF CEO, Bill Moroney, commented, “As always, we are pleased to see a continued investment in US equestrian sport. This significant commitment to world class facilities, horse and rider welfare, and USEF and FEI competitions further validates the market’s demand, at all levels, for organized sport.” Andreas Helgstrand, co-owner and CEO of GEG added, “The Winter Equestrian Festival and PBIEC are fantastic brands within international equestrian sport. Together, we will strengthen the offering and create a global market leader spreading our passion for equestrian sport and lifestyle to new markets.” Outside of equestrian events the Group is active in other equestrian investments including Helgstrand Dressage, Ludger Beerbaum Stables, Helgstrand Jewellery, and the equestrian apparel and accessories company Kingsland Equestrian. At present, the total revenue of these combined is USD180 million.
GEG will now have event venues in the US, Germany, and Denmark. The partnership will benefit from knowledge sharing and a strengthened positioning of PBIEC within show jumping where Ludger Beerbaum Stables has a unique market position. Furthermore, the partnership enables the Group to leverage PBIEC’s experience and create a European equestrian sports event company. ”Our goal is to enhance equestrian sport by providing superior venues and top sport so riders across the world can live out their passions and dreams. With the acquisition of PBIEC, we now have the perfect setting to do this in the US and with our current expansion of Riesenbeck International in Germany we will have two top professional and attractive show grounds,” says Ludger Beerbaum, four-time Olympic gold medalist in jumping and co-owner of Global Equestrian Group. Bellissimo added, “We are pleased to be collaborating with both Andreas and Ludger, whose passion and commitment to equestrian sport is extraordinary. Opportunities abound to take the sport to a new level.” GEG and WEP are evaluating further investment opportunities in Wellington including a new state-of-the-art Global Dressage Festival showgrounds. Bellissimo will be announcing a comprehensive strategy and a series of investments to elevate Wellington as the World’s premiere equestrian lifestyle destination thus strengthening its international appeal. "The acquisition of PBIEC establishes Global Equestrian Group as a true global market leader in equestrian sports with a strong financial foundation and exciting growth opportunities,” says Kaspar Kristiansen, Managing Director, Waterland Nordic.
About Palm Beach International Equestrian Center
Palm Beach International Equestrian Center (PBIEC) was founded by Mark Bellissimo and Wellington Equestrian Partners in 2006 and has contributed to transforming both equestrian sport and Wellington, Florida’s position as the world’s premiere destination for equestrian enthusiasts. PBIEC arranges 40 weeks of events and operates the Winter Equestrian Festival through its management company, Equestrian Sport Productions. The Winter Equestrian Festival, held over 13 weeks, is the world’s largest and longest-running equestrian sports event with more than 8,000 horses and participants from 50 states and 43 countries. Over 250,000 spectators attend the events. www.pbiec.com
About Global Equestrian Group
Global Equestrian Group is the world’s leading equestrian sports group based on a strategic partnership between internationally acclaimed Helgstrand and Ludger Beerbaum Stables as well as Palm Beach International Equestrian Center and private equity firm Waterland. The Group has 250 full-time employees. Global Equestrian Group has activities in dressage, show jumping and events as well as the jewellery company Helgstrand Jewellery and equestrian apparel and accessories company Kingsland Equestrian as well as other equestrian sports investments. www.globalequestriangroup.com
About Waterland
Waterland is an independent private equity investment group that supports entrepreneurs in realizing their growth ambitions. With substantial financial resources from the firm’s eighth fund of EUR 2.6 billion and committed industry expertise, Waterland enables its portfolio companies to achieve accelerated growth both organically and through acquisitions. To date, Waterland has made investments in over 700 companies. Waterland consistently achieve top tier investment ratings among private equity firms and is the only fund that has consistently been in the top 5 in the HEC/Dow Jones Private Equity Performance Ranking for 10 years. Waterland manages more than EUR 9 billion of investor commitments and has offices in Denmark, the Netherlands, Belgium, Germany, Switzerland, Poland, France, Ireland, and the UK. www.waterland.nu
View source version on businesswire.com: https://www.businesswire.com/news/home/20210709005400/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
